Mga Batayang Estadistika
| LEI | 549300K2J28BOC6FBO89 |
| CIK | 1831915 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cytek Biosciences, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
Cytek Biosciences Reports Second Quarter 2025 Financial Results EX-99.1 Exhibit 99.1 Cytek Biosciences Reports Second Quarter 2025 Financial Results FREMONT, Calif., August 6, 2025 (GLOBE NEWSWIRE) – Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2025. Second Quarter Highlights • Total revenue for the second quarter of 20 |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001 |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission F |
|
| May 30, 2025 |
SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 47215 Lakeview Boulevard Fremont, California 94538 (Address of principal |
|
| May 8, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 8, 2025 |
Cytek Biosciences Reports First Quarter 2025 Financial Results Exhibit 99.1 Cytek Biosciences Reports First Quarter 2025 Financial Results FREMONT, Calif., May 8, 2025 (GLOBE NEWSWIRE) – Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2025. First Quarter Highlights • Total revenue for the first quarter of 2025 was $41.5 m |
|
| May 8, 2025 |
November 29, 2022 Dear Philippe: CYTEK BIOSCIENCES, INC. (“Cytek” or the “Company”) is pleased to offer you the position of General Manager, EMEA. You will report to Todd Garland, Chief Commercial Officer, on your duties at Cytek. Your home base office will be 42715 Lakeview Blvd., Fremont, CA 94358. The Company may change your position, duties, and work location from time to time as it deems nece |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 00 |
|
| April 28, 2025 |
TABLE OF CONTENTS SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2025 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 28, 2025 |
As filed with the Securities and Exchange Commission on February 28, 2025 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No. |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-406 |
|
| February 28, 2025 |
Exhibit 10.18 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (“First Amendment”) is made and entered into as of October 28, 2024, by and between DHC ZB PROPERTIES LLC, a Maryland limited liability company (“Landlord”), and CYTEK BIOSCIENCES, INC., a Delaware corporation (“Tenant”). R E C I T A L S : A.SNH Medical Office Properties Trust (predecessor-in-interest to Landlord) (the “Original |
|
| February 28, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Cytek Biosciences, Inc. |
|
| February 28, 2025 |
Exhibit 19.1 INSIDER TRADING POLICY APPROVED BY THE BOARD OF DIRECTORS ON JUNE 30, 2021; AMENDED BY THE NOMINATING AND CORPORATE GOVERNANCE COMMITTEE ON MAY 24, 2022 PURPOSE This Insider Trading Policy (the “Policy”) determines acceptable transactions in the securities of Cytek Biosciences, Inc. (together with its subsidiaries, the “Company” or “Cytek”) by our employees, directors and consultants. |
|
| February 28, 2025 |
List of Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Cytek Biosciences, Inc. Name Jurisdiction Cytek Biosciences B.V. Netherlands Cytek Biosciences GmbH Germany Cytek Biosciences Ltd United Kingdon Cytek Biosciences Pte. Ltd. Singapore Cytek Biosciences S.A.S. France Cytek Japan Corporation Japan Cytek Limited Hong Kong Cytek (Shanghai) Biosciences Co., Ltd. China Cytek (Wuxi) Biosciences Co. Ltd. China |
|
| February 27, 2025 |
Exhibit 99.1 Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook FREMONT, Calif., February 27, 2025 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2024. Recent Highlights • To |
|
| February 27, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissi |
|
| February 14, 2025 |
EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedu |
|
| January 15, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2025 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissio |
|
| January 15, 2025 |
Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results Exhibit 99.1 Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results FREMONT, Calif., January 15, 2025 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2024. Cytek expects its full year revenue for 2024 to be between $200 million and $201 m |
|
| November 14, 2024 |
SC 13G 1 p24-3176sc13g.htm CYTEK BIOSCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cytek Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 23285D109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check |
|
| November 14, 2024 |
CTKB / Cytek Biosciences, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment SC 13G/A 1 fp0090934-11sc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 1)* Cytek Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 23285D1 |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Numbe |
|
| November 5, 2024 |
Cytek Biosciences Reports Third Quarter 2024 Financial Results Exhibit 99.1 Cytek Biosciences Reports Third Quarter 2024 Financial Results FREMONT, Calif., November 5, 2024 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights • Total revenue for the third quarter of 2024 was $51.5 |
|
| November 5, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissio |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissi |
|
| August 6, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission |
|
| August 6, 2024 |
Cytek Biosciences Reports Second Quarter 2024 Financial Results Exhibit 99.1 Cytek Biosciences Reports Second Quarter 2024 Financial Results FREMONT, Calif., August 6, 2024 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights • Total revenue for the second quarter of 2024 was $46.6 mil |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001 |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 47215 Lakeview Boulevard Fremont, California 94538 (Address of principal ex |
|
| May 8, 2024 |
ffer letter, by and between Cytek Biosciences, Inc. and Allen Poirson, Ph.D., dated March 23, 2021 Allen Poirson, Ph.D. Dear Allen, CYTEK BIOSCIENCES, INC. (“Cytek” or the “Company”) is pleased to offer you the position of Senior Vice President of Marketing and Corporate Development. You will report to me directly on your duties at Cytek. You will work at 46107 Landing Parkway, Fremont, CA 94538. The Company may change your position, duties, and work location from time to time as |
|
| May 8, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 8, 2024 |
Cytek Biosciences Reports First Quarter 2024 Financial Results Exhibit 99.1 Cytek Biosciences Reports First Quarter 2024 Financial Results FREMONT, Calif., May 8, 2024 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights • Total revenue was $44.9 million, representing a 21% increase o |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 00 |
|
| May 8, 2024 |
Amended and Restated Severance Benefit Plan CYTEK BIOSCIENCES, INC. SECOND AMENDED AND RESTATED SEVERANCE BENEFIT PLAN AND SUMMARY PLAN DESCRIPTION (Adopted January 1, 2020; as amended and restated on July 15, 2021 and February 20, 2024) 1.Introduction. The purpose of this Cytek Biosciences, Inc. Second Amended and Restated Severance Benefit Plan (the “Plan”) is to provide assurances of specified severance benefits to eligible executives of |
|
| April 25, 2024 |
TABLE OF CONTENTS SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 25, 2024 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 19, 2024 |
Exhibit 99.1 Cytek® Biosciences Names William McCombe Chief Financial Officer Experienced executive with extensive background as CFO for global corporations across dynamic sectors Cytek reaffirms 2024 outlook FREMONT, Calif., March 19, 2024 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that William (Bill) McCombe has been appointed chief financial officer of the company |
|
| March 19, 2024 |
Exhibit 10.1 February 22, 2024 William (Bill) McCombe [email protected] Dear Bill, CYTEK BIOSCIENCES, INC. (“Cytek” or the “Company”) is pleased to offer you the position of Chief Financial Officer. You will serve as Principal Financial and Accounting Officer for purposes of SEC reporting. You will report to Wenbin Jiang, CEO, on your duties at Cytek. You will work at 47215 Lakeview Boulevard, F |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2024 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission |
|
| March 14, 2024 |
As filed with the Securities and Exchange Commission on March 14, 2024 As filed with the Securities and Exchange Commission on March 14, 2024 Registration No. |
|
| March 14, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Cytek Biosciences, Inc. |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-406 |
|
| March 13, 2024 |
List of Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Cytek Biosciences, Inc. Name Jurisdiction Cytek (Shanghai) Biosciences Co., Ltd. China Cytek (Wuxi) Biosciences Co. Ltd. China Cytek Biosciences B.V. Netherlands Cytek Japan Corporation Japan Cytek Biosciences Ltd United Kingdon Cytek Biosciences GmbH Germany Cytek Limited Hong Kong |
|
| March 13, 2024 |
Cytek Biosciences, Inc. Incentive Compensation Recoupment Policy exhibit97clawbackpolicya 288030384 v2 INCENTIVE COMPENSATION RECOUPMENT POLICY APPROVED BY THE BOARD OF DIRECTORS ON NOVEMBER 14, 2023 1. |
|
| March 1, 2024 |
OMB APPROVAL SEC FILE NUMBER 001-40632 CUSIP NUMBER 23285D 109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissi |
|
| March 1, 2024 |
EX-99.1 Exhibit 99.1 Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook FREMONT, Calif., February 28, 2024 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2023. Recent Highlig |
|
| March 1, 2024 |
EX-99.2 Exhibit 99.2 Q4 2023 Earnings Call Event Details Date: 2024-02-28 Company: Cytek Biosciences, Inc. Ticker: CTKB-US Company Participants Unverified Participant MANAGEMENT DISCUSSION SECTION Operator 00:00:11 Good day and thank you for standing by. Welcome to the Cytek Biosciences Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all participants are in a listen-onl |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissi |
|
| February 22, 2024 |
CTKB / Cytek Biosciences, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment SC 13G 1 tm247074d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cytek Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 23285D109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 22, 2024 |
Exhibit 1: Joint Filing Agreement EX-99.1 2 tm247074d1ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 22, 2024 is by and among RA Capital Management, L.P., Peter Kolchinsky and Rajeev Shah (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or |
|
| February 14, 2024 |
US23285D1090 / Cytek Biosciences, Inc. / Yan Ming - SC 13G/A Passive Investment SC 13G/A 1 d608847dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (AMENDMENT NO. 1) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Cytek Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 23285D 109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2024 |
US23285D1090 / Cytek Biosciences, Inc. / BROWN CAPITAL MANAGEMENT LLC Passive Investment SC 13G 1 fp0086869-1sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 0)* Cytek Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 Par Value Per Share (Title of Class of Securities) 23285D109 ( |
|
| February 14, 2024 |
SC 13G/A 1 p24-0576sc13ga.htm CYTEK BIOSCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cytek Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 23285D109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) |
|
| February 14, 2024 |
US23285D1090 / Cytek Biosciences, Inc. / Jiang Wenbin - SC 13G/A Passive Investment SC 13G/A 1 d784915dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (AMENDMENT NO. 1) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Cytek Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 23285D 109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 13, 2024 |
US23285D1090 / Cytek Biosciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0725-cytekbiosciencesinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Cytek Biosciences Inc Title of Class of Securities: Common Stock CUSIP Number: 23285D109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to des |
|
| January 9, 2024 |
Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results EX-99.1 Exhibit 99.1 Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results FREMONT, Calif., January 8, 2024 - Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2023. Cytek expects its full year revenue for 2023 to be near the high end of the company’s most r |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission |
|
| November 28, 2023 |
Corporate Presentation November 2023 Dr. Wenbin Jiang, CEO Patrik Jeanmonod, CFO Paul Goodson, Investor Relations Exhibit 99.1 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek’s business and operational goals and strategies; Cytek’s business dev |
|
| November 28, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissi |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Numbe |
|
| November 13, 2023 |
NT 10-Q OMB APPROVAL SEC FILE NUMBER 001-40632 CUSIP NUMBER 23285D 109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissio |
|
| November 9, 2023 |
Exhibit 99.1 Q3 2023 Earnings Call • Event Details Date: 2023-11-07 Company: Cytek Biosciences, Inc. Ticker: CTKB-US • Company Participants Paul Goodson - Cytek Biosciences, Inc., Head-Investor Relations Wenbin Jiang - Cytek Biosciences, Inc., Co-Founder, Chief Executive Officer & Chairman Patrik Sebastian Jeanmonod - Cytek Biosciences, Inc., Chief Financial Officer • Other Participants David West |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissio |
|
| November 7, 2023 |
Cytek Biosciences Reports Third Quarter 2023 Financial Results Exhibit 99.1 Cytek Biosciences Reports Third Quarter 2023 Financial Results FREMONT, Calif., November 7, 2023 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights • Total revenue was $48.0 million, representing 19% gro |
|
| September 19, 2023 |
US23285D1090 / Cytek Biosciences, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Cytek Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 23285D109 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Nam |
|
| August 8, 2023 |
Cytek Biosciences Reports Second Quarter 2023 Financial Results EX-99.1 Exhibit 99.1 Cytek Biosciences Reports Second Quarter 2023 Financial Results FREMONT, Calif., August 8, 2023 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2023. Recent Highlights • Total revenue was $49.7 million, representing 24% growth over the second quarter of 2022 • Tot |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40632 CYTEK BIOSC |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission F |
|
| May 15, 2023 |
Cytek Biosciences, Inc. Unaudited Pro Forma Condensed Combined Financial Information EX-99.2 Exhibit 99.2 Cytek Biosciences, Inc. Unaudited Pro Forma Condensed Combined Financial Information On February 28, 2023, Cytek Biosciences, Inc. (the “Company” or “acquirer”) acquired certain assets and liabilities related to the flow cytometry and imaging business unit (the “FCI business unit”) from Luminex Corporation (“Luminex”), a wholly owned subsidiary of DiaSorin, S.p.A. (FTSE MIB: D |
|
| May 15, 2023 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No.1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorpo |
|
| May 15, 2023 |
Report of Independent Auditors EX-99.1 Exhibit 99.1 Flow Cytometry Product Line (A Product Line of Luminex Corporation) Abbreviated Financial Statements As of and for the year ended December 31, 2022 Page Abbreviated Financial Statements: Report of Independent Auditors 1 Statement of Assets Acquired and Liabilities Assumed as of December 31, 2022 3 Statement of Revenues and Direct Expenses for the year ended December 31, 2022 4 |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40632 CYTEK BIOS |
|
| May 9, 2023 |
Offer letter, by and between Cytek Biosciences, Inc. and Valerie Barnett, dated January 12, 2021. EX-10 2 ctkb-ex101.htm EX-10.1 January 12, 2021 Valerie Barnett Dear Valerie, CYTEK BIOSCIENCES INC. ("Cytek" or the "Company") is pleased to offer you the position of General Counsel - Vice President of Legal. You will report to WenBin Jiang, CEO, on your duties at Cytek. You will work from 46107 Landing Pkwy, Fremont, CA 94538. The Company may change your position, duties, and work location from |
|
| May 9, 2023 |
Cytek Biosciences Reports First Quarter 2023 Financial Results Exhibit 99.1 Cytek Biosciences Reports First Quarter 2023 Financial Results FREMONT, Calif., May 9, 2023 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the first quarter ended March 31, 2023. First Quarter Highlights • Total revenue was $37.1 million, or $38.1 million on a constant currency basis, representing 6% and |
|
| April 28, 2023 |
TABLE OF CONTENTS SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2023 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 2, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Cytek Biosciences, Inc. |
|
| March 2, 2023 |
As filed with the Securities and Exchange Commission on March 2, 2023 S-8 As filed with the Securities and Exchange Commission on March 2, 2023 Registration No. |
|
| March 1, 2023 |
[***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40632 CYTEK BIOSCIENC |
|
| March 1, 2023 |
List of Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Cytek Biosciences, Inc. Name Jurisdiction Cytek (Shanghai) BioSciences Co., Ltd. China Cytek (Wuxi) BioSciences Co. Ltd. China Cytek (Shanghai) Software Development Technology Co., Ltd. China Cytek Biosciences B.V. Netherlands Cytek Japan Corporation Japan |
|
| March 1, 2023 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the common stock, $0.001 par value per share (“common stock”) of Cytek Biosciences, Inc. (the “Company,” “we,” “our,” or “us”), which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissi |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissi |
|
| February 28, 2023 |
EX-99.1 Exhibit 99.1 Cytek Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results 2022 revenue increased 32%, and 34% on constant currency basis, compared to prior year Expects full year 2023 revenue of $225 million to $235 million, or growth of 37% to 43% over full year 2022 FREMONT, Calif., February 28, 2023 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cy |
|
| February 14, 2023 |
SC 13G/A 1 p23-0180sc13ga.htm CYTEK BIOSCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cytek Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 23285D109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) |
|
| February 13, 2023 |
Exhibit 99.1 CYTEK® BIOSCIENCES TO ACQUIRE FLOW CYTOMETRY AND IMAGING BUSINESS FROM DIASORIN • SALE OF ASSETS RELATED TO FLOW CYTOMETRY & IMAGING (FCI) BUSINESS UNIT • ACQUISITION WILL EXPAND CYTEK’S PRODUCT PORTFOLIO TO INCLUDE IMAGING AND MENU-BASED APPLICATION DRIVEN FLOW CYTOMETRY TO PROVIDE FULL CELL ANALYSIS SOLUTIONS TO ITS CUSTOMERS • TRANSACTION IS IN LINE WITH DIASORIN’S STRATEGIC PRIORI |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissi |
|
| February 9, 2023 |
US23285D1090 / Cytek Biosciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv0701-cytekbiosciencesinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Cytek Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 23285D109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuan |
|
| November 9, 2022 |
Exhibit 10.1 Cytek Biosciences, INC. Stock Option Grant Notice (2021 Equity Incentive Plan) Cytek Biosciences, Inc. (the ?Company?), pursuant to its 2021 Equity Incentive Plan (the ?Plan?), has granted to you (?Optionholder?) an option to purchase the number of shares of the Common Stock set forth below (the ?Option?). Your Option is subject to all of the terms and conditions as set forth in this |
|
| November 9, 2022 |
Exhibit 10.2 Cytek Biosciences, INC. RSU AWARD GRANT NOTICE (2021 EQUITY INCENTIVE PLAN) Cytek Biosciences, Inc. (the ?Company?) has awarded to you (the ?Participant?) the number of restricted stock units specified and on the terms set forth below (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions as set forth in this RSU Award Grant Notice (the "Grant Notice"), the Co |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40632 CYTEK |
|
| November 9, 2022 |
Exhibit 99.1 Cytek Biosciences Reports Third Quarter 2022 Financial Results Third quarter revenue grew 18% compared to prior year quarter Improved gross margins, net income, and adjusted EBITDA over prior year quarter FREMONT, Calif., November 9, 2022 (GLOBE NEWSWIRE) ? Cytek? Biosciences, Inc. (?Cytek Biosciences? or ?Cytek?) (Nasdaq: CTKB) today reported financial results for the third quarter e |
|
| November 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissio |
|
| November 1, 2022 |
Exhibit 99.1 Cytek? Biosciences Names Chris Williams Chief Operating Officer Experienced Biotech, Pharmaceutical Industry Leader to Guide Operations Growth and Scalability FREMONT, Calif., October 31, 2022 ? Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Chris Williams has been appointed chief operating officer for the company. In this role, Williams will lead and execute the company? |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2022 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissio |
|
| November 1, 2022 |
Offer Letter dated October 4, 2022, between Chris Williams and the Company Exhibit 10.1 October 4, 2022 Chris Williams Dear Chris, CYTEK BIOSCIENCES, INC. (?Cytek? or the ?Company?) is pleased to offer you the position of Chief Operating Officer. You will report to Wenbin Jiang, CEO, on your duties at Cytek. You will work at 47215 Lakeview Boulevard, Fremont, CA 94538. The Company may change your position, duties, and work location from time to time as it deems necessary |
|
| August 26, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 CYTEK BIOSCIENCES, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF CYTEK BIOSCIENCES, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between CYTEK BIOSCIENCES, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing un |
|
| August 26, 2022 |
Power of Attorney. Reference is made to the signature pages of this Form S-3. Table of Contents As filed with the Securities and Exchange Commission on August 26, 2022 Registration No. |
|
| August 26, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Cytek Biosciences, Inc. |
|
| August 26, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.8 CYTEK BIOSCIENCES, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF CYTEK BIOSCIENCES, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between CYTEK BIOSCIENCES, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and ex |
|
| August 26, 2022 |
Exhibit 4.4 Cytek Biosciences, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 8 Sec |
|
| August 26, 2022 |
EX-1.2 2 d661781dex12.htm EX-1.2 Exhibit 1.2 CYTEK BIOSCIENCES, INC. EQUITY DISTRIBUTION AGREEMENT August 26, 2022 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), Cytek Biosciences, Inc., a company organized under the laws of Delaware (the “Company”), proposes to issue and sell f |
|
| August 26, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.7 CYTEK BIOSCIENCES, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF CYTEK BIOSCIENCES, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between CYTEK BIOSCIENCES, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and ex |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40632 CYTEK BIOSC |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission |
|
| August 10, 2022 |
Exhibit 99.1 Cytek Biosciences Reports Second Quarter 2022 Financial Results Second quarter revenue grew 32% compared to prior year FREMONT, Calif., August 10, 2022 (GLOBE NEWSWIRE) ? Cytek? Biosciences, Inc. (?Cytek Biosciences? or ?Cytek?) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2022. Recent Highlights ? Total revenue was $40.2 million for the second |
|
| August 3, 2022 |
Joint Filing Agreement attached as Exhibit 99.1 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be |
|
| August 3, 2022 |
US23285D1090 / Cytek Biosciences, Inc. / 3E Bioventures Capital, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Cytek Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 23285D109 (CUSIP Number) August 3, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| June 6, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2022 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40632 CYTEK BIOS |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 11, 2022 |
Exhibit 99.1 Cytek Biosciences Reports First Quarter 2022 Financial Results First quarter revenue grew 44% compared to prior year FREMONT, Calif., May 11, 2022 (GLOBE NEWSWIRE) ? Cytek? Biosciences, Inc. (?Cytek Biosciences? or ?Cytek?) (Nasdaq: CTKB) today reported financial results for the first quarter ended March 31, 2022. Recent Highlights ? Total revenue was $35.1 million for the first quart |
|
| April 14, 2022 |
TABLE OF CONTENTS ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defi |
|
| March 17, 2022 |
List of Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of Cytek Biosciences, Inc. Name Jurisdiction Cytek (Shanghai) BioSciences Co., Ltd. China Cytek (Wuxi) BioSciences Co. Ltd. China Cytek (Shanghai) Software Development Technology Co., Ltd. China Cytek Biosciences B.V. Netherlands Cytek Japan Corporation Japan |
|
| March 17, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Cytek Biosciences, Inc. |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40632 CYTEK BIOSCIENC |
|
| March 17, 2022 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the common stock, $0.001 par value per share (?common stock?) of Cytek Biosciences, Inc. (the ?Company,? ?we,? ?our,? or ?us?), which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of |
|
| March 17, 2022 |
As filed with the Securities and Exchange Commission on March 17, 2022 As filed with the Securities and Exchange Commission on March 17, 2022 Registration No. |
|
| March 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Cytek BioSciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 23285D109 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Nam |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2022 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissi |
|
| February 28, 2022 |
US23285D1090 / Cytek Biosciences, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment 1)* Cytek BioSciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 23285D109 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Name, A |
|
| February 23, 2022 |
Exhibit 99.1 Cytek Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results 2021 Revenue Increased 38% Compared to Prior Year FREMONT, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) ? Cytek? Biosciences, Inc. (?Cytek Biosciences? or ?Cytek?) (Nasdaq: CTKB) today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Highlights ? Total revenue was $38 |
|
| February 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissi |
|
| February 17, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be |
|
| February 17, 2022 |
US23285D1090 / Cytek Biosciences, Inc. / 3E Bioventures Capital, L.P. Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cytek Biosciences, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 23285D109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 14, 2022 |
US23285D1090 / Cytek Biosciences, Inc. / Yan Ming - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Cytek Biosciences, Inc. |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Cytek Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 23285D109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant |
|
| February 14, 2022 |
US23285D1090 / Cytek Biosciences, Inc. / Jiang Wenbin - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Cytek Biosciences, Inc. |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2021 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissi |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40632 CYTEK BIOSCIENCES, INC. |
|
| November 12, 2021 |
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. |
|
| November 12, 2021 |
Exhibit 10.2 Cytek Biosciences, INC. RSU AWARD GRANT NOTICE (2021 EQUITY INCENTIVE PLAN) Cytek Biosciences, Inc. (the ?Company?) has awarded to you (the ?Participant?) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company |
|
| November 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commissio |
|
| November 8, 2021 |
Exhibit 99.1 Cytek Biosciences Reports Third Quarter 2021 Financial Results Third quarter total revenue growth of 37% compared to prior year FREMONT, Calif., Nov. 8, 2021 (GLOBE NEWSWIRE) ? Cytek? Biosciences, Inc. (?Cytek Biosciences? or ?Cytek?) (Nasdaq: CTKB) today reported financial results for the third quarter ended September 30, 2021. Recent Highlights ? Total revenue was $34.4 million for |
|
| September 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A Amendment No. |
|
| September 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d187138d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2021 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of |
|
| September 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40632 CYTEK BIOSCIENCES, INC. |
|
| September 3, 2021 |
Cytek Biosciences Reports Second Quarter 2021 Financial Results Exhibit 99.1 Cytek Biosciences Reports Second Quarter 2021 Financial Results FREMONT, Calif., Sept. 2, 2021 (GLOBE NEWSWIRE) ? Cytek? Biosciences, Inc. (?Cytek Biosciences? or ?Cytek?) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2021. Recent Highlights ? Revenue was $30.4 million for the second quarter, representing a 59% increase over the second quarter o |
|
| August 30, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2021 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission |
|
| August 6, 2021 |
CTKB / Cytek Biosciences, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Cytek BioSciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 23285D109 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Attn: Peter Kolchinsky Telephone: 617.778.2500 (Name, Addr |
|
| July 27, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF CYTEK BIOSCIENCES, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS PAGE ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS? MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 5 Section 7. Notice of Mee |
|
| July 27, 2021 |
Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CYTEK BIOSCIENCES, INC. Wenbin Jiang hereby certifies that: ONE: The name of this corporation is Cytek Biosciences, Inc., and the original Certificate of Incorporation of this corporation was filed with the Secretary of State of the State of Delaware on December 15, 2014 under the name Cytoville, Inc. TWO: He is the duly elected and |
|
| July 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2021 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40632 47-2547526 (State or other jurisdiction of incorporation) (Commission F |
|
| July 23, 2021 |
14,564,635 Shares COMMON STOCK Table of Contents Index to Financial Statements Filed Pursuant to Rule 424(b)(4) Registration No. |
|
| July 23, 2021 |
As filed with the U.S. Securities and Exchange Commission on July 23, 2021 As filed with the U.S. Securities and Exchange Commission on July 23, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYTEK BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 47-2547526 (State or other jurisdiction of Incorporation or organization) (I.R |
|
| July 20, 2021 |
CYTEK BIOSCIENCES, INC. 46107 Landing Parkway Fremont, CA 94538 CYTEK BIOSCIENCES, INC. 46107 Landing Parkway Fremont, CA 94538 July 20, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Taylor Beech Dietrich King Eric Atallah Mary Mast Re: Cytek Biosciences, Inc. Registration Statement on Form S-1, as amended (File No. 333-257663) Request for Acceleration of Effective Date La |
|
| July 19, 2021 |
Form of common stock certificate of Cytek Biosciences, Inc. EX-4.1 Exhibit 4.1 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CUSIP 23285D 10 9 SEE REVERSE FOR CERTAIN DEFINITIONS AND LEGENDS This certifies that is the record holder of CYTEK BIOSCIENCES, INC. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate properly endorsed. This CERTIFICATE Certificate is not valid until counte |
|
| July 19, 2021 |
List of Subsidiaries of Cytek Biosciences, Inc. Exhibit 21.1 Subsidiaries of Cytek Biosciences, Inc. Name Jurisdiction Cytek (Shanghai) BioSciences Co., Ltd. China Cytek (Wuxi) BioSciences Co. Ltd. China Cytek (Shanghai) Software Development Technology Co., Ltd. China Cytek Biosciences B.V. Netherlands Cytek Japan Corporation Japan |
|
| July 19, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CYTEK BIOSCIENCES, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) CYTEK BIOSCIENCES, INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. That th |
|
| July 19, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 [?] Shares CYTEK BIOSCIENCES, INC. COMMON STOCK (PAR VALUE $0.001 PER SHARE) UNDERWRITING AGREEMENT [?], 2021 [?], 2021 Morgan Stanley & Co. LLC Goldman Sachs & Co. LLC Piper Sandler & Co. Cowen and Company, LLC As Representatives of the several Underwriters named in Schedule II hereto c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 c/o Goldman Sachs & Co. LLC 200 West St |
|
| July 19, 2021 |
As filed with the U.S. Securities and Exchange Commission on July 19, 2021. S-1/A 1 d80783ds1a.htm AMENDMENT NO. 2 TO FORM S-1 Table of Contents Index to Financial Statements As filed with the U.S. Securities and Exchange Commission on July 19, 2021. Registration No. 333-257663 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYTEK BIOSCIENCES, INC. (Exact name of Re |
|
| July 19, 2021 |
Forms of Option Agreement and Notice of Stock Option Grant under 2021 Equity Incentive Plan. Exhibit 10.5 CYTEK BIOSCIENCES, INC. STOCK OPTION GRANT NOTICE (2021 EQUITY INCENTIVE PLAN) Cytek Biosciences, Inc. (the ?Company?), pursuant to its 2021 Equity Incentive Plan (the ?Plan?), has granted to you (?Optionholder?) an option to purchase the number of shares of the Common Stock set forth below (the ?Option?). Your Option is subject to all of the terms and conditions as set forth in this |
|
| July 19, 2021 |
Cytek Biosciences, Inc. 2021 Employee Stock Purchase Plan. Exhibit 10.6 CYTEK BIOSCIENCES, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: , 2021 APPROVED BY THE STOCKHOLDERS: , 2021 IPO DATE: , 2021 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain eligible Employees of designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan |
|
| July 19, 2021 |
Exhibit 10.7 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this ?Agreement?) dated as of , 2021, is made by and between CYTEK BIOSCIENCES, INC., a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. B. The Company?s amended and restated bylaws (the |
|
| July 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Cytek Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 47-2547526 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No. |
|
| July 19, 2021 |
Cytek Biosciences, Inc. Amended and Restated Severance Benefit Plan. Exhibit 10.9 CYTEK BIOSCIENCES, INC. 2021 AMENDED AND RESTATED SEVERANCE BENEFIT PLAN AND SUMMARY PLAN DESCRIPTION (Effective January 1, 2020; as amended and restated on , 2021) 1. Introduction. The purpose of this Cytek Biosciences, Inc. 2021 Amended and Restated Severance Benefit Plan (the ?Plan?) is to provide assurances of specified severance benefits to eligible executives of the Company whos |
|
| July 19, 2021 |
Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF CYTEK BIOSCIENCES, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS PAGE ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS? MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 5 Section 7. Notice of Mee |
|
| July 19, 2021 |
Cytek Biosciences, Inc. 2021 Equity Incentive Plan. Exhibit 10.4 CYTEK BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: , 2021 APPROVED BY THE STOCKHOLDERS: , 2021 1. GENERAL. (a) Defined Terms. Except as otherwise provided, any capitalized term shall have the meaning provided in Section 14 of this Plan. (b) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. A |
|
| July 19, 2021 |
Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CYTEK BIOSCIENCES, INC. Wenbin Jiang hereby certifies that: ONE: The name of this corporation is Cytek Biosciences, Inc., and the original Certificate of Incorporation of this corporation was filed with the Secretary of State of the State of Delaware on December 15, 2014 under the name Cytoville, Inc. TWO: He is the duly elected and |
|
| July 14, 2021 |
As filed with the U.S. Securities and Exchange Commission on July 13, 2021. Table of Contents Index to Financial Statements As filed with the U.S. Securities and Exchange Commission on July 13, 2021. Registration No. 333-257663 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYTEK BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 3826 |
|
| July 13, 2021 |
Gordon Ho +1 650 843 5190 [email protected] July 13, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Taylor Beech Dietrich King Eric Atallah Mary Mast Re: Cytek Biosciences, Inc. Registration Statement on Form S-1 Filed July 2, 2021 File No. 333-257663 Ladies and Gentlemen: On behalf of Cytek Biosciences, Inc. (the ?Company? |
|
| July 2, 2021 |
Cytek Biosciences, Inc. 2015 Equity Incentive Plan, as amended. Exhibit 10.2 CYTEK BIOSCIENCES, INC. AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: March 26, 2015 APPROVED BY THE STOCKHOLDERS: March 26, 2015 AMENDED BY THE BOARD OF DIRECTORS: December 27, 2016 APPROVED BY THE STOCKHOLDERS: December 27,2016 AMENDED BY THE BOARD OF DIRECTORS: November 13, 2017 APPROVED BY THE STOCKHOLDERS: November 13, 2017 AMENDED BY THE BOAR |
|
| July 2, 2021 |
EX-10.3 6 d80783dex103.htm EX-10.3 Exhibit 10.3 CYTEK BIOSCIENCES, INC. STOCK OPTION GRANT NOTICE (2015 EQUITY INCENTIVE PLAN) CYTEK BIOSCIENCES, INC. (the “Company”), pursuant to its 2015 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditio |
|
| July 2, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CYTEK BIOSCIENCES, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) CYTEK BIOSCIENCES, INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That th |
|
| July 2, 2021 |
Offer letter, by and between Cytek Biosciences, Inc. and Patrik Jeanmonod, dated October 5, 2018. EX-10.9 7 d80783dex109.htm EX-10.9 Exhibit 10.9 10/5/18 Patrik Sebastian Jeanmonod Re: Chief Financial Officer Dear Patrik, CYTEK BIOSCIENCES INC. (“Cytek” or the “Company”) is pleased to offer you the position of Chief Financial Officer (CFO). Your duties are captured in the attached Job Description. You will report to Dr. Wenbin Jiang, CEO of Cytek Biosciences. You will work in the facility loca |
|
| July 2, 2021 |
Power of Attorney. Reference is made to the signature page hereto. Table of Contents Index to Financial Statements As filed with the U.S. Securities and Exchange Commission on July 2, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYTEK BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 3826 47-2547526 (State or othe |
|
| July 2, 2021 |
Exhibit 10.1 CYTEK BIOSCIENCES, INC. AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT (this ?Agreement?), is made as of the 23rd day of October, 2020, by and among Cytek BioSciences, Inc., a Delaware corporation (the ?Company?), each of the investors listed on Schedule A hereto, each of which is |
|
| July 2, 2021 |
Exhibit 10.11 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUPPLY & LICENSE AGREEMENT This Supply and License Agreement (this “Agreement”), made as of September 1, 2020 (“Effective Date”), is by and between BIOTIUM, INC. (“BIOTIUM”), a Calif |
|
| July 2, 2021 |
Lease, by and between Crest Properties LLC and Cytek Biosciences, Inc., dated as of July 24, 2015. EX-10.13 10 d80783dex1013.htm EX-10.13 Exhibit 10.13 AIR COMMERCIAL REAL ESTATE ASSOCIATION STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE - NET 1. Basic Provisions (“Basic Provisions”). 1.1 Parties: This Lease (“Lease”), dated for reference purposes only July 24, 2015, is made by and between Crest Properties LLC (“Lessor”) and Cytoville, Inc., a Delaware Corporation (“Lessee”), (collectively t |
|
| July 2, 2021 |
Gordon Ho +1 650 843 5190 [email protected] July 2, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Taylor Beech Dietrich King Eric Atallah Mary Mast Re: Cytek Biosciences, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted June 14, 2021 CIK No. 0001831915 Ladies and Gentlemen: On behalf of Cytek Bios |
|
| July 2, 2021 |
Bylaws of Cytek Biosciences, Inc., as currently in effect. EX-3.3 3 d80783dex33.htm EX-3.3 Exhibit 3.3 BYLAWS OF CYTEK BIOSCIENCES, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS PAGE ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meeting 1 Section 6. Special Meetings 3 Section 7. Not |
|
| July 2, 2021 |
EX-10.14 11 d80783dex1014.htm EX-10.14 Exhibit 10.14 LEASE BY AND BETWEEN SNH MEDICAL OFFICE PROPERTIES TRUST, a Maryland real estate investment trust, as Landlord, AND CYTEK BIOSCIENCES, INC., a Delaware corporation, as Tenant 47215/47211 Lakeview Boulevard, Fremont, California 94538 Table of Contents Page ARTICLE 1 Reference Data 1 1.1 Introduction and Subjects Referred To. 1 1.2 Exhibits 4 ARTI |
|
| July 2, 2021 |
Exhibit 10.12 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SETTLEMENT, LICENSE, AND EQUITY ISSUANCE AGREEMENT This SETTLEMENT, LICENSE, AND EQUITY ISSUANCE AGREEMENT (this ?Agreement?) is made and entered into as of October 5, 2020 (the ?Eff |
|
| June 14, 2021 |
EX-10.9 2 filename2.htm Exhibit 10.9 10/5/18 Patrik Sebastian Jeanmonod Re: Chief Financial Officer Dear Patrik, CYTEK BIOSCIENCES INC. (“Cytek” or the “Company”) is pleased to offer you the position of Chief Financial Officer (CFO). Your duties are captured in the attached Job Description. You will report to Dr. Wenbin Jiang, CEO of Cytek Biosciences. You will work in the facility located at 4610 |
|
| June 14, 2021 |
Table of Contents Index to Financial Statements As confidentially submitted to the U. |
|
| June 14, 2021 |
SETTLEMENT, LICENSE, AND EQUITY ISSUANCE AGREEMENT Exhibit 10.12 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SETTLEMENT, LICENSE, AND EQUITY ISSUANCE AGREEMENT This SETTLEMENT, LICENSE, AND EQUITY ISSUANCE AGREEMENT (this ?Agreement?) is made and entered into as of October 5, 2020 (the ?Eff |
|
| June 14, 2021 |
Exhibit 10.11 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUPPLY & LICENSE AGREEMENT This Supply and License Agreement (this ?Agreement?), made as of September 1, 2020 (?Effective Date?), is by and between BIOTIUM, INC. (?BIOTIUM?), a Calif |
|
| June 14, 2021 |
Gordon Ho +1 650 843 5190 [email protected] June 14, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Taylor Beech Dietrich King Eric Atallah Mary Mast Re: Cytek Biosciences, Inc. Draft Registration Statement on Form S-1 Submitted April 22, 2021 CIK No. 0001831915 Ladies and Gentlemen: On behalf of Cytek Biosciences, Inc. (th |
|
| June 14, 2021 |
AIR COMMERCIAL REAL ESTATE ASSOCIATION STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE - NET EX-10.13 5 filename5.htm Exhibit 10.13 AIR COMMERCIAL REAL ESTATE ASSOCIATION STANDARD INDUSTRIAL/COMMERCIAL MULTI-TENANT LEASE - NET 1. Basic Provisions (“Basic Provisions”). 1.1 Parties: This Lease (“Lease”), dated for reference purposes only July 24, 2015, is made by and between Crest Properties LLC (“Lessor”) and Cytoville, Inc., a Delaware Corporation (“Lessee”), (collectively the “Parties”, |
|
| June 14, 2021 |
EX-10.14 6 filename6.htm Exhibit 10.14 LEASE BY AND BETWEEN SNH MEDICAL OFFICE PROPERTIES TRUST, a Maryland real estate investment trust, as Landlord, AND CYTEK BIOSCIENCES, INC., a Delaware corporation, as Tenant 47215/47211 Lakeview Boulevard, Fremont, California 94538 Table of Contents Page ARTICLE 1 Reference Data 1 1.1 Introduction and Subjects Referred To. 1 1.2 Exhibits 4 ARTICLE 2 Premises |
|
| April 22, 2021 |
CYTEK BIOSCIENCES, INC. STOCK OPTION GRANT NOTICE (2015 EQUITY INCENTIVE PLAN) EX-10.3 6 filename6.htm Exhibit 10.3 CYTEK BIOSCIENCES, INC. STOCK OPTION GRANT NOTICE (2015 EQUITY INCENTIVE PLAN) CYTEK BIOSCIENCES, INC. (the “Company”), pursuant to its 2015 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set f |
|
| April 22, 2021 |
EX-10.11 7 filename7.htm Exhibit 10.11 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SUPPLY & LICENSE AGREEMENT This Supply and License Agreement (this “Agreement”), made as of September 1, 2020 (“Effective Date”), is by and between BIOTIUM, |
|
| April 22, 2021 |
BYLAWS CYTEK BIOSCIENCES, INC. (A DELAWARE CORPORATION) EX-3.3 3 filename3.htm Exhibit 3.3 BYLAWS OF CYTEK BIOSCIENCES, INC. (A DELAWARE CORPORATION) TABLE OF CONTENTS PAGE ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS’ MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meeting 1 Section 6. Special Meetings 3 Section 7. Notice of Me |
|
| April 22, 2021 |
Exhibit 10.2 CYTEK BIOSCIENCES, INC. AMENDED AND RESTATED 2015 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: March 26, 2015 APPROVED BY THE STOCKHOLDERS: March 26, 2015 AMENDED BY THE BOARD OF DIRECTORS: December 27, 2016 APPROVED BY THE STOCKHOLDERS: December 27,2016 AMENDED BY THE BOARD OF DIRECTORS: November 13, 2017 APPROVED BY THE STOCKHOLDERS: November 13, 2017 AMENDED BY THE BOAR |
|
| April 22, 2021 |
SETTLEMENT, LICENSE, AND EQUITY ISSUANCE AGREEMENT EX-10.12 8 filename8.htm Exhibit 10.12 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SETTLEMENT, LICENSE, AND EQUITY ISSUANCE AGREEMENT This SETTLEMENT, LICENSE, AND EQUITY ISSUANCE AGREEMENT (this “Agreement”) is made and entered into as of |
|
| April 22, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CYTEK BIOSCIENCES, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) CYTEK BIOSCIENCES, INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: 1. That th |
|
| April 22, 2021 |
CYTEK BIOSCIENCES, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT EX-10.1 4 filename4.htm Exhibit 10.1 CYTEK BIOSCIENCES, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 23rd day of October, 2020, by and among Cytek BioSciences, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A h |
|
| April 22, 2021 |
Table of Contents Index to Financial Statements As confidentially submitted to the U. |
